Loading.......  

RabAvert Rabies Vaccine

Rabies is a deadly, but preventable disease. It is caused by a virus that affects the central nervous system of humans and other mammals. Usually, people get rabies when they are bitten by an infected (rabid) animal.1 In about 100 countries worldwide, rabies is found in wild and/or domestic animals and poses a threat to more than 3 billion people living in these areas.2 An estimated 55,000 rabies deaths are reported globally every year, and up to 50% of all rabies victims are children.3

RabAvert Rabies Vaccine is indicated for preexposure vaccination, in both primary series and booster doses, and for postexposure prophylaxis against rabies in all age groups.4

Please scroll down to see Important Safety Information

RabAvert is the most widely used cell culture rabies vaccine5

  • More than 55 million doses administered worldwide since 1985
  • Expiration dating of up to 4 years

Available without supply restrictions for both pre-exposure immunization and postexposure prophylaxis.6

Included in the Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) recommendations for human rabies prevention7

  • Pre-exposure vaccination
  • Booster immunization
  • Postexposure prophylaxis

Presentation

 

RabAvert is packaged in a one dose kit which contains the following4

  • 1 vial of freeze-dried vaccine containing a single dose
  • 1 vial of Sterile Diluent for RabAvert (1 mL)
  • 1 disposable syringe
  • 1 smaller needle for injection, 25 gauge x 1”
  • 1 longer needle for reconstitution, 21 gauge x 1.5”

NDC # 63851-501-01
Manufactured in Marburg, Germany

 

Important Safety Information

Anaphylaxis, encephalitis including death, meningitis, neuroparalytic events such as encephalitis, transient paralysis, Guillain-Barre Syndrome, myelitis, and retrobulbar neuritis; and multiple sclerosis have been reported to be temporally associated with the use of RabAvert.4

The most commonly occurring adverse reactions are injection site reactions, such as injection site erythema, induration and pain; flu-like symptoms, such as asthenia, fatigue, fever, headache, myalgia and malaise; arthralgia, dizziness, lymphadenopathy, nausea, and rash.4

History of anaphylaxis to the vaccine or any of the vaccine components constitutes a contraindication to preexposure vaccination with this vaccine. In the case of postexposure prophylaxis, if an alternative product is not available, the patient should be vaccinated with caution with the necessary medical equipment and emergency supplies available and observed carefully after vaccination. A patient’s risk of acquiring rabies must be carefully considered before deciding to discontinue vaccination.4

Please click here to see the US Full Prescribing Information for RabAvert®.

 

References

  1. Centers for Disease Control and Prevention. Rabies.http://www.cdc.gov/rabies/.Accessed February 12, 2014
  2. World Health Organization. Rabies vaccines: WHO position paper.http://www.who.int/entity/wer/2010/wer8532.pdf. Accessed February 12, 2014.
  3. Centers for Disease Control and Prevention. CDC Features: September 28 is a day to learn how you can prevent and control rabies, everyday.http://www.cdc.gov/features/rabies/. Accessed February 12, 2014.
  4. RabAvert Prescribing Information. Cambridge, MA: Novartis Vaccines, Inc; 2012
  5. Data on file. Novartis Vaccines, Inc.
  6. Centers for Disease Control and Prevention. Vaccine and immune globulin availability. http://www.cdc.gov/rabies/resources/availability.html. Accessed February 12, 2014.
  7. Manning SE, Rupprecht CE, Fishbein D, et al. Human rabies prevention— United States, 2008: recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2008;57(RR03) :1-26,28.

Other Vaccines

  • IXIARO®
  •  
    (Japanese Encephalitis Vaccine, Inactivated, Adsorbed)
  • Menveo®
  •  
    [Meningococcal (Groups A, C, Y and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine]